#HMU26 - Twitter Hashtag

4 months ago

An incredible close to #ANCO #HMU26, bringing together multidisciplinary experts and cutting-edge insights across hematologic malignancies, from precision medicine to cellular therapies, all shaping the future of patient-centered care.

0

2

0

81

ANCO

@ANCO_News

4 months ago

Dr. Lisa Law @kpnorcal presents evolving first-line CLL strategies, emphasizing time-limited venetoclax combinations versus continuous BTK inhibitor therapy based on patient risk and goals. #ANCO #HMU26

ANCO_News's tweet photo. Dr. Lisa Law @kpnorcal presents evolving first-line CLL strategies, emphasizing time-limited venetoclax combinations versus continuous BTK inhibitor therapy based on patient risk and goals. #ANCO #HMU26 https://t.co/x1aGjFMzTN

0

3

0

1

110

ANCO

@ANCO_News

4 months ago

Dr. Vanessa Kennedy @vekennedy @StanfordMed discusses evolving AML treatment strategies, highlighting HMA/venetoclax as a frontline option, improved event-free survival, and the growing role of MRD-guided, risk-adapted care. #ANCO #HMU26

ANCO_News's tweet photo. Dr. Vanessa Kennedy @vekennedy @StanfordMed discusses evolving AML treatment strategies, highlighting HMA/venetoclax as a frontline option, improved event-free survival, and the growing role of MRD-guided, risk-adapted care. #ANCO #HMU26 https://t.co/8wN9KohnHi

0

2

0

1

76

ANCO

@ANCO_News

4 months ago

Dr. Aaron Logan @hemedoc @UCSFCancer highlights measurable residual disease as the central driver of treatment decisions in adult ALL, with NGS MRD guiding risk stratification and the integration of blinatumomab improving outcomes even in MRD negative patients. #ANCO #HMU26